0000950170-24-071393.txt : 20240610 0000950170-24-071393.hdr.sgml : 20240610 20240610165850 ACCESSION NUMBER: 0000950170-24-071393 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240606 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moukheibir Catherine CENTRAL INDEX KEY: 0001772130 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 241033559 MAIL ADDRESS: STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC. STREET 2: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 FORMER NAME: FORMER CONFORMED NAME: Moukheibir Catherine Michener DATE OF NAME CHANGE: 20190328 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-06-06 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001772130 Moukheibir Catherine C/O IRONWOOD PHARMACEUTICALS, INC. 100 SUMMER STREET, SUITE 2300 BOSTON MA 02110 true false false false false Class A Common Stock 2024-06-06 4 S false 44426 6.36 D 84207 D Class A Common Stock 2024-06-07 4 S false 35574 6.61 D 48633 D The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.56 to $6.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Brian Tessler, Attorney-in-Fact 2024-06-10